Premium
TOPICAL TREATMENT WITH BAY b 5097, A NEW BROAD SPECTRUM ANTIMYCOTIC AGENT
Author(s) -
FREDRIKSSON TORSTEN
Publication year - 1972
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.1972.tb05079.x
Subject(s) - trichophyton , candida albicans , dermatology , medicine , placebo , bay , broad spectrum , randomized controlled trial , traditional medicine , surgery , antifungal , biology , pathology , microbiology and biotechnology , chemistry , alternative medicine , civil engineering , combinatorial chemistry , engineering
Summary.— The effect on superficial mycoses of BAY b 5097, a tritylimidazole derivative, applied topically in a 1% solution, was evaluated in a randomized double‐blind study in 54 patients. It was significantly better than a placebo in diseases produced both by Candida albicans and by Trichophyton species. After 3 weeks of treatment, clinical healing was recorded in 57% of the cases and marked improvement in an additional 33%. No side effects were noted.